Bayer CEO Is Confident on Monsanto, 2017 Growth

The transcript discusses the company's confidence in maintaining earnings momentum and growth in 2017, driven by strong performance in pharma, consumer health, and other sectors. It addresses concerns about the Monsanto deal, highlighting progress in financing and regulatory discussions. The company also discusses its strong cash flow and the lack of recent contact with Warren Buffett. Finally, it outlines challenges in the European market and emphasizes growth opportunities in Asia and the US.

What is the company's strategy for managing cash flow and investments?

In what regions does the company see more growth opportunities compared to Europe?